You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜明昂科-B(01541.HK):IMM2510聯合化療進行NSCLC一線治療的IB/II期臨牀試驗完成首例患者給藥
格隆匯 01-13 20:33

格隆匯1月13日丨宜明昂科-B(01541.HK)公吿,IMM2510聯合化療進行非小細胞肺癌(NSCLC)一線治療的Ib/II期臨牀試驗成功完成首例患者給藥。安全性導入期後,公司計劃在上述臨牀試驗中招募一線患者,預計最早於2025年下半年發佈初步臨牀數據,包括來自NSCLC一線患者的數據。

IMM2510I期劑量遞增研究的臨牀數據顯示出令人鼓舞的療效跡象:數名曾接受多種療法失敗的晚期實體瘤患者在接受IMM2510治療後達到部分緩解(PR)。截至2024年12月31日,招募超過100名患者加入IMM2510單藥治療的I/II期臨牀試驗。在多種實體瘤適應症(包括NSCLC、三陰性乳腺癌(TNBC)及軟組織肉瘤(STS)等重複治療失敗的患者)中觀察到良好的耐受性及有前景的初步PR信號。

IMM2510由集團自主研發,是一款靶向血管內皮生長因子(VEGF)及程序性細胞死亡配體1(PD-L1)的雙特異性分子,採用單克隆抗體—受體重組蛋白(mAbTrap)結構。IMM2510能夠抑制血管生成,使腫瘤縮小,並使腫瘤細胞對免疫反應更敏感,同時通過阻斷PD-L1╱程序性細胞死亡蛋白1(PD-1)相互作用及誘導Fc介導的抗體依賴的細胞毒性作用(ADCC)╱抗體依賴的細胞吞噬作用(ADCP)活性激活T細胞、自然殺傷細胞及巨噬細胞。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account